We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bio-Rad (BIO) Earnings Miss Estimates in Q3, Revenues Beat
Read MoreHide Full Article
Bio-Rad Laboratories, Inc. (BIO - Free Report) posted third-quarter 2018 adjusted earnings per share (EPS) of 91 cents, which missed the Zacks Consensus Estimate of $1.16 by 21.6%. Earnings declined 10.8% from the prior-year quarter.
Revenues in Detail
Revenues in the quarter totaled $545.1 million, beating the Zacks Consensus Estimate by 1.1%. Revenues improved 2.1% from the year-ago quarter and rose 3.4% at constant currency (cc).
Per management, solid demand across many of its key product lines led to growth across most geographical regions.
Segmental Analysis
Sales at the Life Sciences segment totaled $206.6 million, up 7.1% year over year and 8% at cc. Per management, the upside reflects higher sales in the cell biology, droplet Digital PCR and food safety product lines. Further, the company continues to see increased demand for its process media product lines.
On a geographic basis, sales at cc were particularly strong in the United States, China and India.
Bio-Rad Laboratories, Inc. Price, Consensus and EPS Surprise
Net sales at Clinical Diagnostics in the third quarter totaled $334 million, down 1.2% on a year-over-year basis. However, sales were up 0.5% at cc. The upside in the currency neutral sales indicates growth in immunology, diabetes monitoring, blood typing and quality-control product lines.
Geographically, sales rose in the Americas and Asia, partially offset by a decline in Europe.
Margins
Gross profit in the reported quarter totaled $286.7 million, down 4.1% from the prior-year quarter. Gross margin came in at 52.6%, down 340 basis points (bps). Per the company, changes in product mix, high service, warranty and reagent rental costs, along with extra inventory related expenses led to the decline in gross margin.
Adjusted gross margin came in at 53.5%, down 340 bps year over year.
Operating income grossed $36.3, down 6.4% from the year-ago quarter.
Guidance Updated
For 2018, the company reiterated revenue growth guidance at 4-4.5% (cc). The Zacks Consensus Estimate for the same is pegged at $2.72 billion.
Full-year operating margin is now projected in the 8-9% range from 10% stated earlier.
Our Take
Bio-Rad exited third-quarter 2018 on mixed note. We are however encouraged with the year-over-year rise in earnings and revenues. Sales growth at the Clinical Diagnostics segment was impressive as well. The company also saw strong growth in the Life Science segment and cell biology, Digital PCR and food safety product lines. Further, solid revenue growth in geographies like North America, China and Asia Pacific buoys optimism.
We are also upbeat about the company’s recent 510(k) clearance from the FDA for the IH-Reader 24, a semi-automated blood typing instrument designed for medium- to small-volume laboratories.
However, challenges associated with the implementation of the global ERP system raise concerns.
Intuitive Surgical reported third-quarter 2018 adjusted EPS of $2.83, which beat the Zacks Consensus Estimate of $2.65. Revenues totaled $920.9 million, also surpassing the consensus estimate of $918.6 million.
Stryker posted third-quarter 2018 adjusted EPS of $1.69, steering past the Zacks Consensus Estimate of $1.68. Operating margin was 17.8%, up 30 bps.
Merit Medical reported third-quarter 2018 adjusted EPS of 47 cents, which trumped the Zacks Consensus Estimate of 42 cents. Revenues of $221.6 million edged past the consensus estimate of $218 million.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Bio-Rad (BIO) Earnings Miss Estimates in Q3, Revenues Beat
Bio-Rad Laboratories, Inc. (BIO - Free Report) posted third-quarter 2018 adjusted earnings per share (EPS) of 91 cents, which missed the Zacks Consensus Estimate of $1.16 by 21.6%. Earnings declined 10.8% from the prior-year quarter.
Revenues in Detail
Revenues in the quarter totaled $545.1 million, beating the Zacks Consensus Estimate by 1.1%. Revenues improved 2.1% from the year-ago quarter and rose 3.4% at constant currency (cc).
Per management, solid demand across many of its key product lines led to growth across most geographical regions.
Segmental Analysis
Sales at the Life Sciences segment totaled $206.6 million, up 7.1% year over year and 8% at cc. Per management, the upside reflects higher sales in the cell biology, droplet Digital PCR and food safety product lines. Further, the company continues to see increased demand for its process media product lines.
On a geographic basis, sales at cc were particularly strong in the United States, China and India.
Bio-Rad Laboratories, Inc. Price, Consensus and EPS Surprise
Bio-Rad Laboratories, Inc. Price, Consensus and EPS Surprise | Bio-Rad Laboratories, Inc. Quote
Net sales at Clinical Diagnostics in the third quarter totaled $334 million, down 1.2% on a year-over-year basis. However, sales were up 0.5% at cc. The upside in the currency neutral sales indicates growth in immunology, diabetes monitoring, blood typing and quality-control product lines.
Geographically, sales rose in the Americas and Asia, partially offset by a decline in Europe.
Margins
Gross profit in the reported quarter totaled $286.7 million, down 4.1% from the prior-year quarter. Gross margin came in at 52.6%, down 340 basis points (bps). Per the company, changes in product mix, high service, warranty and reagent rental costs, along with extra inventory related expenses led to the decline in gross margin.
Adjusted gross margin came in at 53.5%, down 340 bps year over year.
Operating income grossed $36.3, down 6.4% from the year-ago quarter.
Guidance Updated
For 2018, the company reiterated revenue growth guidance at 4-4.5% (cc). The Zacks Consensus Estimate for the same is pegged at $2.72 billion.
Full-year operating margin is now projected in the 8-9% range from 10% stated earlier.
Our Take
Bio-Rad exited third-quarter 2018 on mixed note. We are however encouraged with the year-over-year rise in earnings and revenues. Sales growth at the Clinical Diagnostics segment was impressive as well. The company also saw strong growth in the Life Science segment and cell biology, Digital PCR and food safety product lines. Further, solid revenue growth in geographies like North America, China and Asia Pacific buoys optimism.
We are also upbeat about the company’s recent 510(k) clearance from the FDA for the IH-Reader 24, a semi-automated blood typing instrument designed for medium- to small-volume laboratories.
However, challenges associated with the implementation of the global ERP system raise concerns.
Zacks Rank & Key Picks
Bio-Rad has a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space, which reported solid earnings this season, are Intuitive Surgical (ISRG - Free Report) , Stryker Corporation (SYK - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) . All the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Intuitive Surgical reported third-quarter 2018 adjusted EPS of $2.83, which beat the Zacks Consensus Estimate of $2.65. Revenues totaled $920.9 million, also surpassing the consensus estimate of $918.6 million.
Stryker posted third-quarter 2018 adjusted EPS of $1.69, steering past the Zacks Consensus Estimate of $1.68. Operating margin was 17.8%, up 30 bps.
Merit Medical reported third-quarter 2018 adjusted EPS of 47 cents, which trumped the Zacks Consensus Estimate of 42 cents. Revenues of $221.6 million edged past the consensus estimate of $218 million.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>